J&J will make initial payments of $785 million, including a $465 million equity investment, plus up to $140 million in milestone payments, with Sail contributing its endless RNA (eRNA) and targeted nanoparticle delivery technology
Supporting studies L-Carnitine does not have an authorised EU health claim
E., Welting, O., Wouters, M
Factors such as research dose, dose-escalation schedule, hydration, nutrition, existing medical conditions, and concurrent medications may all influence how a person responds
The major drawback of oral form of glutathione is its low bioavailability in humans.[] PARENTERAL PREPARATIONS To achieve the anticipated therapeutic levels and rapid onset of action, IV glutathione has been made available
Over time, laboratory studies began to investigate its theoretical benefits on musculoskeletal and neural tissues